4147.TWO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 08:30):

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases...

Stats
Dzisiejszy wolumen	499 686
Średni wolumen	2.40M
Kapitalizacja rynkowa	21.00B
EPS	TWD0 ( 2024-03-11 )
Następna data zysków	( TWD0 ) 2024-05-08
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-109.21
ATR14	TWD0.0670 (0.08%)

Wolumen Korelacja

Długi: -0.07 (neutral)

Krótki: -0.84 (strong negative)

Signal:(43.984) Neutral

TaiMed Biologics Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TaiMed Biologics Inc. Korelacja - Waluta/Towar

-0.24
( neutral )

0.42
( neutral )

0.00
( neutral )

-0.61
( weak negative )

-0.20
( neutral )

0.67
( moderate )

TaiMed Biologics Inc. Finanse

Annual	2023
Przychody:	TWD491.78M
Zysk brutto:	TWD225.23M (45.80 %)
EPS:	TWD-0.760

FY	2023
Przychody:	TWD491.78M
Zysk brutto:	TWD225.23M (45.80 %)
EPS:	TWD-0.760

FY	2022
Przychody:	TWD563.01M
Zysk brutto:	TWD215.71M (38.31 %)
EPS:	TWD-1.090

FY	2021
Przychody:	TWD413.44M
Zysk brutto:	TWD83.96M (20.31 %)
EPS:	TWD-1.867

Financial Reports:

No articles found.

TaiMed Biologics Inc.

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.